Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OncoSec Medical (ONCS), a biopharmaceutical company, has signed an exclusive cGMP manufacturing agreement with VGXI for the production of interleukin-12 plasmid DNA (DNA IL-12).
Subscribe to our email newsletter
The agreement uses VGXI’s patented DNA plasmid manufacturing process and leverages VGXI’s expertise for large-scale process development and clinical manufacturing for DNA IL-12 for use in OncoSec’s OMS ElectroImmunotherapy program.
OncoSec president and chief executive officer Punit Dhillon said VGXI was selected for its manufacturing activities based upon its ability to produce to commercial specifications and its leadership position in cGMP manufacturing of plasmid DNA for clinical use.
"In addition, the facility meets FDA cGMP compliance standards for manufacturing of biopharmaceutical products," Dhillon added.
OMS ElectroImmunotherapy is currently being developed for the treatment of metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma.